VIVUS, Inc. (Nasdaq: VVUS) today announced that it has initiated an open label safety study (TA-314) with its investigational drug ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE